This Week in Cardiology — Jun 6, 2026

Welcome to This Week in Cardiology. This week we're covering 10 notable papers spanning the optimization of medical therapy for atherosclerotic disease, the expanding role of finerenone in chronic kidney disease, new insights from advanced imaging an… This week's papers: 1. P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis. — European heart journal 2026 2. Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REA… — European heart journal 2026 3. Finerenone in Persons with Chronic Kidney Disease without Diabetes. — The New England journal of medicine 2026 4. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. — JAMA 2026 5. Cardiac Lipid Metabolism: Cells, Metabolites, and Rhythms. — Circulation research 2026 6. Incremental Prognostic Value of Subendocardial Myocardial Flow Reserve in Patients With Normal Perfusion. — Circulation 2026 7. ATAD3A Limits Aortic Dissection via Mito-Lysosome Contacts and Lipoylation. — Circulation research 2026 8. Safety of low lipoprotein(a) levels: the FOURIER trial. — European heart journal 2026 9. Estimating the Effects of MTEER in U.S. Practice: A Transportability Analysis of the COAPT Trial. — Journal of the American College of Cardiology 2026 Listen at https://audioscholar.cc/episode/tsamessqwc